HSA
RPRX icon

Hussman Strategic Advisors’s Royalty Pharma RPRX Stock Holding History

Hussman Strategic Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.18M Hold
21,000
– – 0.27% 165
2026
Q1 		$1.01M Sell
21,000
-42,000
-67% -$1.84M 0.22% 193
2025
Q4 		$2.43M Buy
+63,000
New +$2.4M 0.59% 60

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Hussman Strategic Advisors's RPRX Position: Q2 2026 in Review

Hussman Strategic Advisors held its Royalty Pharma (RPRX) position steady in Q2 2026 at 21,000 shares worth $1.18M. The position accounts for 0.27% of the portfolio, ranked #165.

Hussman Strategic Advisors first reported a position in RPRX in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.43M in Q4 2025. 646 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Hussman Strategic Advisors held 21,000 shares of Royalty Pharma worth $1.18M as of Q2 2026.
  • Hussman Strategic Advisors left its Royalty Pharma share count unchanged in Q2 2026.
  • Royalty Pharma made up 0.27% of Hussman Strategic Advisors's portfolio in Q2 2026, its #165 holding.
  • Hussman Strategic Advisors first reported a position in Royalty Pharma in Q4 2025 and has held it in 3 quarters since.
  • Hussman Strategic Advisors's Royalty Pharma position peaked at $2.43M in Q4 2025.
  • 646 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Hussman Strategic Advisors's 13F filing for Q2 2026, filed 3 Aug 2026.